---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-011295"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:41:01.072929+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics CFO Salvatore Giovine resigns effective Aug 19, 2022

## Summary
- CFO Salvatore Giovine resigned for personal family reasons, effective August 19, 2022.
- No successor or interim CFO was announced in this filing.
- Giovine served as principal financial officer of the company.

## SEC filing metadata
- accession: 0001558370-22-011295
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837022011295/0001558370-22-011295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837022011295/xlo-20220725x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-011295
- JSON: https://secwatch.observer/filing/0001558370-22-011295.json
- Plain text: https://secwatch.observer/filing/0001558370-22-011295.txt

## Key facts
- Executive change
  Salvatore Giovine resigned as chief financial officer at Xilio Therapeutics, Inc..
  - Action: resigned
  - Role: chief financial officer
  source text: On July 25, 2022, Salvatore Giovine notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer (principal financial officer) of the Company, effective August 19, 2022, for personal family reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837022011295/0001558370-22-011295-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.